<DOC>
	<DOCNO>NCT01612884</DOCNO>
	<brief_summary>Personalized treatment approach antiplatelet drug choice propose optimize safety coronary stenting reduce heart attack repeat intervention simultaneously minimize adverse bleeding event . This study compare efficacy two laboratory guide treatment algorithm personalize antiplatelet medication choice coronary stenting</brief_summary>
	<brief_title>Antiplatelet Therapy Guided Thrombelastography Patients With Acute Coronary Syndromes ( TEGCOR Study )</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>Patients admit acute coronary syndrome ( unstable angina , nonST elevation myocardial infarction ) refer coronary angiography . Current therapy clopidogrel ( least 300mg load dose , 75mg po daily &gt; 5 day ) Age range 2175 year . Unable give consent Age young 21 year , great 75 year History stroke Body weight &lt; 60 kg Acute STEMI , Thrombocytopenia &lt; 100'000 , requirement chronic warfarin therapy</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>